Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sincronium
- Development stage
- Phase 3
- Lead developer
- Ferrer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Sincronium is a cardiovascular polypill developed by Ferrer for the secondary prevention of cardiovascular disease. It is a fixed-dose combination (FDC) therapy containing three established pharmacological agents: acetylsalicylic acid (an antiplatelet), simvastatin (a statin), and ramipril (an ACE inhibitor). The drug is designed to simplify treatment regimens for patients with established coronary heart disease, thereby improving medication adherence and concurrently managing multiple risk factors such as hypertension and dyslipidemia. Clinical data, including the Bacus study, demonstrate its effectiveness in improving lipid profiles and blood pressure across various patient demographics, including those with high body mass index.
- Brand names
- SincroniumTrinomiaIltriaNeptuno
- Other names
- CV polypillCardiovascular polypillCNIC-PolypillFerrer Polypillacetylsalicylic acid + simvastatin + ramipril
02
Targets
PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)ACE (Angiotensin Converting Enzyme)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)
Beyond the preview
Go deeper on Sincronium.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sincronium.